Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Gustave Roussy Cancer Campus
Villejuif, FranciaPublications in collaboration with researchers from Gustave Roussy Cancer Campus (18)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
2021
-
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576
2018
-
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
European Urology, Vol. 73, Núm. 3, pp. 462-468
-
Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174
2017
-
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study
Annals of Oncology, Vol. 28, Núm. 12, pp. 3044-3050
-
Predictors of responses to immune checkpoint blockade in advanced melanoma
Nature Communications, Vol. 8, Núm. 1
2016
-
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma
Clinical Cancer Research
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine